JP2007501305A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007501305A5 JP2007501305A5 JP2006522341A JP2006522341A JP2007501305A5 JP 2007501305 A5 JP2007501305 A5 JP 2007501305A5 JP 2006522341 A JP2006522341 A JP 2006522341A JP 2006522341 A JP2006522341 A JP 2006522341A JP 2007501305 A5 JP2007501305 A5 JP 2007501305A5
- Authority
- JP
- Japan
- Prior art keywords
- acetylheparosan
- sulfation
- carried out
- modified
- partial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 39
- 150000004676 glycans Chemical class 0.000 claims description 7
- 229920001282 polysaccharide Polymers 0.000 claims description 7
- 239000005017 polysaccharide Substances 0.000 claims description 7
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 5
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 5
- 229960002442 glucosamine Drugs 0.000 claims description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 4
- 229920000669 heparin Polymers 0.000 claims description 4
- 229960002897 heparin Drugs 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000005670 sulfation reaction Methods 0.000 claims 24
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 230000001180 sulfating effect Effects 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 7
- 230000019635 sulfation Effects 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 238000006345 epimerization reaction Methods 0.000 claims 5
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 239000002798 polar solvent Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 3
- 229940088598 enzyme Drugs 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 206010002388 Angina unstable Diseases 0.000 claims 2
- 230000005526 G1 to G0 transition Effects 0.000 claims 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- 208000007814 Unstable Angina Diseases 0.000 claims 2
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 claims 2
- 238000003381 deacetylation reaction Methods 0.000 claims 2
- 230000002255 enzymatic effect Effects 0.000 claims 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 230000002107 myocardial effect Effects 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000000053 physical method Methods 0.000 claims 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 claims 2
- 239000002994 raw material Substances 0.000 claims 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical group [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims 2
- MCHWWJLLPNDHGL-KVTDHHQDSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-3,4-diol Chemical group OC[C@H]1O[C@H](CO)[C@@H](O)[C@@H]1O MCHWWJLLPNDHGL-KVTDHHQDSA-N 0.000 claims 1
- WKFQMDFSDQFAIC-UHFFFAOYSA-N 2,4-dimethylthiolane 1,1-dioxide Chemical compound CC1CC(C)S(=O)(=O)C1 WKFQMDFSDQFAIC-UHFFFAOYSA-N 0.000 claims 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims 1
- 102000004411 Antithrombin III Human genes 0.000 claims 1
- 108090000935 Antithrombin III Proteins 0.000 claims 1
- 206010003178 Arterial thrombosis Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004593 Epoxy Substances 0.000 claims 1
- 108010029144 Factor IIa Proteins 0.000 claims 1
- 108010074860 Factor Xa Proteins 0.000 claims 1
- 239000007995 HEPES buffer Substances 0.000 claims 1
- 108010022901 Heparin Lyase Proteins 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 101100450563 Mus musculus Serpind1 gene Proteins 0.000 claims 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 1
- 125000003047 N-acetyl group Chemical group 0.000 claims 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims 1
- 239000004793 Polystyrene Substances 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 238000003314 affinity selection Methods 0.000 claims 1
- 230000002744 anti-aggregatory effect Effects 0.000 claims 1
- 230000002785 anti-thrombosis Effects 0.000 claims 1
- 229960005348 antithrombin iii Drugs 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 150000002009 diols Chemical group 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000003480 fibrinolytic effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 claims 1
- AJFDBNQQDYLMJN-UHFFFAOYSA-N n,n-diethylacetamide Chemical compound CCN(CC)C(C)=O AJFDBNQQDYLMJN-UHFFFAOYSA-N 0.000 claims 1
- 230000014508 negative regulation of coagulation Effects 0.000 claims 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 claims 1
- 229920002223 polystyrene Polymers 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 235000010288 sodium nitrite Nutrition 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
- 239000002253 acid Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- AEMOLEFTQBMNLQ-CLQWQSTFSA-N l-iduronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O AEMOLEFTQBMNLQ-CLQWQSTFSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001618A ITMI20031618A1 (it) | 2003-08-06 | 2003-08-06 | Derivati polisaccaridici dotati di alta attivita' |
| PCT/EP2004/051391 WO2005014656A1 (en) | 2003-08-06 | 2004-07-07 | Polysaccharides derivatives with high antithrombotic activity in plasma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007501305A JP2007501305A (ja) | 2007-01-25 |
| JP2007501305A5 true JP2007501305A5 (https=) | 2007-09-06 |
Family
ID=34131211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006522341A Pending JP2007501305A (ja) | 2003-08-06 | 2004-07-07 | 血漿中で高度の抗血栓活性を有する多糖類誘導体 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7687249B2 (https=) |
| EP (1) | EP1654288B9 (https=) |
| JP (1) | JP2007501305A (https=) |
| KR (1) | KR20060063933A (https=) |
| CN (1) | CN1832966A (https=) |
| AT (1) | ATE458009T1 (https=) |
| AU (1) | AU2004262584A1 (https=) |
| BR (1) | BRPI0413346A (https=) |
| CA (1) | CA2534709A1 (https=) |
| DE (1) | DE602004025583D1 (https=) |
| DK (1) | DK1654288T3 (https=) |
| ES (1) | ES2341249T3 (https=) |
| IL (1) | IL173482A0 (https=) |
| IT (1) | ITMI20031618A1 (https=) |
| MX (1) | MXPA06001511A (https=) |
| RU (1) | RU2361881C2 (https=) |
| WO (1) | WO2005014656A1 (https=) |
| ZA (1) | ZA200601643B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006316039B2 (en) * | 2005-11-21 | 2011-08-18 | Ge Healthcare Bio-Sciences Ab | A method of chromatography using semi-synthetic heparin ligands |
| US9498494B2 (en) | 2008-09-11 | 2016-11-22 | Agency For Science, Technology And Research | Glycosaminoglycans |
| GB0818255D0 (en) | 2008-10-06 | 2008-11-12 | Agency Science Tech & Res | Isolation and identification of glycosaminoglycans |
| CN101698838B (zh) * | 2008-12-26 | 2012-05-23 | 北京大学 | 尿苷二磷酸葡萄糖醛酸异构酶及其编码基因与应用 |
| ITMI20091445A1 (it) * | 2009-08-07 | 2011-02-08 | Inalco S P A A Socio Unico | Derivati semi-sintetici del polisaccaride k5 per la prevenzione ed il trattamento del danno tissutale associato a ischemia e/o riperfusione |
| KR101515892B1 (ko) * | 2009-09-01 | 2015-05-04 | 렌슬러 폴리테크닉 인스티튜트 | Ｋ5 헤파로산 발효 및 정제 |
| US9012168B2 (en) | 2010-07-29 | 2015-04-21 | Shire Human Genetic Therapies, Inc. | Assays for detection of glycosaminoglycans |
| EP2809796A4 (en) * | 2012-02-01 | 2016-08-17 | Shire Human Genetic Therapies | TESTS FOR THE DETECTION OF GLYCOSAMINOGLYCANES |
| CN102796723A (zh) * | 2012-09-11 | 2012-11-28 | 深圳市海普瑞药业股份有限公司 | 肝素酶i的固定化方法 |
| CN102888390B (zh) * | 2012-10-30 | 2014-09-03 | 深圳市海普瑞药业股份有限公司 | 肝素酶ⅲ的固定化方法 |
| CN103059165B (zh) * | 2012-12-26 | 2015-04-29 | 安徽丰原药业股份有限公司 | 一种多糖酰化物及其制备方法 |
| HUE053923T2 (hu) | 2015-12-28 | 2021-08-30 | Ajinomoto Kk | Eljárás antikoaguláns aktivitással rendelkezõ heparán-szulfát elõállítására |
| JP6225321B1 (ja) | 2016-08-31 | 2017-11-08 | 王子ホールディングス株式会社 | ポリ硫酸ペントサンの製造方法 |
| EP3677587A4 (en) | 2016-08-31 | 2021-04-14 | Oji Holdings Corporation | XYLOOLIGOSACCHARIDE ACID, AND METHOD FOR MANUFACTURING THE SAME |
| JP6281659B1 (ja) | 2017-02-28 | 2018-02-21 | 王子ホールディングス株式会社 | ポリ硫酸ペントサン、医薬組成物及び抗凝固剤 |
| CA3065747C (en) | 2017-05-31 | 2024-10-01 | Oji Holdings Corporation | MOISTURIZING COMPOSITION CONTAINING PENTOSANNE POLYSULFATE |
| PL3683242T3 (pl) | 2017-09-12 | 2025-03-03 | Oji Holdings Corporation | Polisiarczan pentozanu i sposób wytwarzania polisiarczanu pentozanu |
| KR102533822B1 (ko) | 2017-12-20 | 2023-05-17 | 오지 홀딩스 가부시키가이샤 | 폴리황산펜토산 및 폴리황산펜토산을 포함하는 의약 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1214609B (it) * | 1985-05-17 | 1990-01-18 | Opocrin Spa | Esosaminoglicani solfati depolimerizzati ad attivita'antitrombotica, fibrinolitica, antinfiammatoria, loro procedimento di preparazione e composizioni farmaceutiche che li contengono. |
| FR2669932B1 (fr) | 1990-12-03 | 1994-07-01 | Sanofi Sa | Nouvel heparosane-n,o-sulfate, son procede de preparation et les compositions pharmaceutiques qui le contiennent. |
| IT1271057B (it) | 1994-11-04 | 1997-05-26 | Inalco Spa | Polisaccaridi aventi un elevato contenuto di acido iduronico |
| IT1282994B1 (it) * | 1996-05-10 | 1998-04-03 | Inalco Spa | Derivati del polisaccaride k5 aventi elevata attivita' anticoagulante |
| IT1290814B1 (it) | 1997-03-24 | 1998-12-11 | Istituto Scient Di Chimica E B | Glicosaminoglicani aventi elevata attivita' antitrombotica |
| SE9701454D0 (sv) | 1997-04-18 | 1997-04-18 | Ulf Lindahl | new DNA sequences and a process for enzyme manufacture |
| US20020062019A1 (en) | 2000-03-30 | 2002-05-23 | Pasqua Oreste | Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activities and process for their preparation |
| IT1318432B1 (it) * | 2000-03-30 | 2003-08-25 | Inalco Spa | Glicosaminoglicani derivati dal polisaccaride k5 aventi elevataattivita' anticoagulante ed antitrombotica e processo per la loro |
| ITMI20011633A1 (it) * | 2001-07-27 | 2003-01-27 | San Raffaele Centro Fond | Uso di polisaccaridi batterici supersolfatati inibitori dell'hiv |
| CN1675249A (zh) * | 2002-06-18 | 2005-09-28 | 格利考斯2000有限公司 | N－酰基－(表)k5－胺－o－硫酸盐衍生物及其产品的制备方法 |
-
2003
- 2003-08-06 IT IT001618A patent/ITMI20031618A1/it unknown
-
2004
- 2004-07-07 JP JP2006522341A patent/JP2007501305A/ja active Pending
- 2004-07-07 AT AT04766148T patent/ATE458009T1/de not_active IP Right Cessation
- 2004-07-07 CN CNA2004800223076A patent/CN1832966A/zh active Pending
- 2004-07-07 RU RU2006106790/04A patent/RU2361881C2/ru not_active IP Right Cessation
- 2004-07-07 DE DE602004025583T patent/DE602004025583D1/de not_active Expired - Fee Related
- 2004-07-07 CA CA002534709A patent/CA2534709A1/en not_active Abandoned
- 2004-07-07 WO PCT/EP2004/051391 patent/WO2005014656A1/en not_active Ceased
- 2004-07-07 MX MXPA06001511A patent/MXPA06001511A/es active IP Right Grant
- 2004-07-07 AU AU2004262584A patent/AU2004262584A1/en not_active Abandoned
- 2004-07-07 BR BRPI0413346-3A patent/BRPI0413346A/pt not_active IP Right Cessation
- 2004-07-07 US US10/557,584 patent/US7687249B2/en not_active Expired - Fee Related
- 2004-07-07 KR KR1020067002532A patent/KR20060063933A/ko not_active Withdrawn
- 2004-07-07 EP EP04766148A patent/EP1654288B9/en not_active Expired - Lifetime
- 2004-07-07 ES ES04766148T patent/ES2341249T3/es not_active Expired - Lifetime
- 2004-07-07 DK DK04766148.3T patent/DK1654288T3/da active
-
2006
- 2006-01-31 IL IL173482A patent/IL173482A0/en unknown
- 2006-02-24 ZA ZA200601643A patent/ZA200601643B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007501305A5 (https=) | ||
| Chandarajoti et al. | The design and synthesis of new synthetic low‐molecular‐weight heparins | |
| RU2006106790A (ru) | Производные полисахаридов с высокой антитромботической активностью в плазме | |
| US8193166B2 (en) | Epimerized derivatives of K5 polysaccharide with a very high degree of sulfation | |
| JP4267916B2 (ja) | 多糖体ｋ５から誘導された高度のアンチトロンビン活性を有するグリコサミノグリカン及びその製法 | |
| HUT64087A (en) | Process for producing n,o-sulfated heparosanes of high molecular weigh and pharmaceutical compositions comprising such compounds | |
| US8227449B2 (en) | Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activities and process for their preparation | |
| US20040146994A1 (en) | Glycosaminoglycans derived from the k5 polysaccharide having high anticoagulant and antithrombotic activity and process for their preparation | |
| US7812151B2 (en) | Low molecular weight polysaccharides having antithrombotic activity | |
| US20120108542A1 (en) | Sulfated octasaccharide and its use as antithrombotic agent | |
| US9346893B2 (en) | Process for the preparation of highly O-sulfated, epimerized derivatives of K5 polysacchride and intermediates therein | |
| RU2333222C2 (ru) | Эпимеризованные производные полисахарида к5 с высокой степенью сульфатирования | |
| AU2002222358B2 (en) | Glycosaminoglycans derived from K5 polysaccharide having high antithrombin activity and process for their preparation | |
| Bisio et al. | Carbohydrate‐Based Antithrombotics | |
| Garg et al. | Heparin as a potential therapeutic agent to reverse vascular remodeling |